Physician

Vedashree Enagandula Panthulu, M.D.

According to 2025 Medicare claims, Vedashree Panthulu, M.D. (NPI: 1750510723) practices rheumatology in the Tampa, FL market, with the plurality of this provider's patient population coming from Hillsborough, FL. This provider's primary affiliated billing organization is SUNSHINE RHEUMATOLOGY AND ARTHRITIS CENTER LLC (NPI: 1770071433; TIN: 82-3784465) and primary practice location at 33573-6835.

Panthulu's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 664 traditional Medicare patients, billed 241,814 HCPCS/CPT codes, and received $3,115,917 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 3,716 prescription claims across 882 beneficiaries totaling $2,600,746 in drug costs, led by Humira(Cf) Pen (Adalimumab). 2018 DME data shows 1,436 claims. Open Payments data shows 192 records totaling $53,185. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $95,916 to $3,115,917. Similarly, Part D prescription costs have moved sharply higher in recent years, from $33,839 to $2,600,746. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	390	1,306	$95,916
2016	N/R	N/R	N/R
2017	101	948	$25,606
2018	402	26,253	$434,922
2019	478	91,063	$1,494,626
2020	525	121,103	$2,036,575
2021	602	195,436	$2,345,223
2022	627	232,480	$2,407,588
2023	690	329,957	$3,239,783
2024	664	241,814	$3,115,917

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	115	329	$33,839
2016	106	412	$251,925
2017	181	462	$337,092
2018	425	1,342	$665,256
2019	453	2,226	$815,409
2020	589	3,145	$1,789,459
2021	699	3,618	$2,590,233
2022	704	3,762	$2,739,319
2023	794	3,753	$2,961,437
2024	882	3,716	$2,600,746

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	40	$3,199
2016	N/R	43	$2,164
2017	N/R	38	$1,360
2018	1,422	1,436	$959,105
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	475	869	$101
96413	Administration of chemotherapy into vein, 1 hour or less	89	402	$101
96401	Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle	256	1,264	$56
J0897	Injection, denosumab, 1 mg	167	13,920	$21
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	544	1,027	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Humira(Cf) Pen	Adalimumab	76	2,408	$601,555
Orencia Clickject	Abatacept	42	1,400	$283,220
Enbrel Sureclick	Etanercept	36	1,008	$263,554
Rinvoq	Upadacitinib	32	960	$210,532
Benlysta	Belimumab	32	896	$157,427

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	188	$4,611	Amgen Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	4	$48,574	Amgen Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Vedashree Enagandula Panthulu, M.D.?

Tedicare shows public-source Medicare data for Vedashree Enagandula Panthulu, M.D. (NPI 1750510723), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Vedashree Enagandula Panthulu, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Vedashree Enagandula Panthulu, M.D.?

Vedashree Enagandula Panthulu, M.D. is linked to SUNSHINE RHEUMATOLOGY AND ARTHRITIS CENTER LLC (billing NPI 1770071433) in the available physician profile data.

Does Vedashree Enagandula Panthulu, M.D. have Open Payments data?

Vedashree Enagandula Panthulu, M.D. has 192 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.